Proteome Sciences PLC Director shareholding (0495H)

TIDMPRM

RNS Number : 0495H

Proteome Sciences PLC

01 April 2022

1 April 2022

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Director shareholding

The Company has been notified that the shareholding of Vulpes Life Sciences Fund ("Vulpes") remains unchanged at 65,826,194 ordinary shares, representing 22.3 per cent of the share capital, but that the holding has been transferred to a new custodian to hold the shares on Vulpes' behalf.

Martin Diggle, Non-Executive Director of Proteome Sciences, is a director and partner of Vulpes Investment Management Private Limited which manages Vulpes. Accordingly, the notification table below in regard to Martin Diggle is made in accordance with the requirements of the UK Market Abuse regulation.

For further information please contact:

 
 Proteome Sciences plc 
  Mariola Soehngen, M.D., Chief Executive Officer 
 Dr Ian Pike, Chief Scientific Officer       Tel: +44 (0)20 7043 2116 
  Richard Dennis, Chief Commercial Officer 
 
 Allenby Capital Limited (AIM Nominated Adviser & Broker) 
 John Depasquale / Jeremy Porter             Tel: +44 (0) 20 3328 5656

About Proteome Sciences plc. ( www.proteomics.com )

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant(R) and TMT(R)MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator(TM) provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1.   Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name:                                      Martin Diggle 
     -----------------------------------------  ------------------------------ 
 2.   Reason for the notification 
     ------------------------------------------------------------------------- 
 a)   Position/status:                           Non-Executive Director 
     -----------------------------------------  ------------------------------ 
 b)   Initial notification/Amendment:            Initial Notification 
     -----------------------------------------  ------------------------------ 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------------- 
 a)   Name:                                      Proteome Sciences Plc 
     -----------------------------------------  ------------------------------ 
 b)   LEI:                                       213800Q62ICXANKU2986 
     -----------------------------------------  ------------------------------ 
 4.   Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
     ------------------------------------------------------------------------- 
 a)   Description of the financial instrument,   Ordinary Shares of 1p nominal 
       type of instrument:                        value 
       Identification code:                       GB0003104196 
     -----------------------------------------  ------------------------------ 
 b)   Nature of the transaction:                 Transfer of registered 
                                                  holding to new custodian 
     -----------------------------------------  ------------------------------ 
 c)   Price(s) and volume(s):                      Price(s)   Volume(s) 
                                                    0p         52,445,715 
                                                              ----------- 
     -----------------------------------------  ------------------------------ 
 d)   Aggregated information:                    Same as 4c) above. 
        *    Aggregated volume: 
 
 
        *    Price: 
     -----------------------------------------  ------------------------------ 
 e)   Date of the transaction:                   28 March 2022 
     -----------------------------------------  ------------------------------ 
 f)   Place of the transaction:                  Outside a trading venue 
     -----------------------------------------  ------------------------------

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHUPUMACUPPGQG

(END) Dow Jones Newswires

April 01, 2022 13:01 ET (17:01 GMT)

Proteome Sciences (AQSE:PRM.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024